AR128877A1 - CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LOS MISMOS - Google Patents

CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LOS MISMOS

Info

Publication number
AR128877A1
AR128877A1 ARP230100734A ARP230100734A AR128877A1 AR 128877 A1 AR128877 A1 AR 128877A1 AR P230100734 A ARP230100734 A AR P230100734A AR P230100734 A ARP230100734 A AR P230100734A AR 128877 A1 AR128877 A1 AR 128877A1
Authority
AR
Argentina
Prior art keywords
pnpla3
expression
rnai
methods
rnai constructs
Prior art date
Application number
ARP230100734A
Other languages
English (en)
Spanish (es)
Inventor
Justin K Murray
Bryan Meade
Ingrid Rulifson
Oliver Homann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR128877A1 publication Critical patent/AR128877A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y203/00Acyltransferases (2.3)
    • C12Y203/01Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/010511-Acylglycerol-3-phosphate O-acyltransferase (2.3.1.51)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004Phospholipase A2 (3.1.1.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/0104Orsellinate-depside hydrolase (3.1.1.40)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/353Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP230100734A 2022-03-23 2023-03-23 CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LOS MISMOS AR128877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263322845P 2022-03-23 2022-03-23

Publications (1)

Publication Number Publication Date
AR128877A1 true AR128877A1 (es) 2024-06-19

Family

ID=88102183

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100734A AR128877A1 (es) 2022-03-23 2023-03-23 CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LOS MISMOS

Country Status (13)

Country Link
US (1) US20250207138A1 (https=)
EP (1) EP4496893A2 (https=)
JP (1) JP2025512771A (https=)
KR (1) KR20240162559A (https=)
CN (1) CN118891364A (https=)
AR (1) AR128877A1 (https=)
AU (1) AU2023237880A1 (https=)
CA (1) CA3254112A1 (https=)
CL (1) CL2024002802A1 (https=)
IL (1) IL315078A (https=)
MX (1) MX2024011595A (https=)
TW (1) TW202345869A (https=)
WO (1) WO2023183801A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252063A1 (zh) * 2024-06-04 2025-12-11 正大天晴药业集团股份有限公司 靶向pnpla3的双链核糖核酸

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2976445A1 (en) * 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
TW202542311A (zh) * 2018-09-19 2025-11-01 美商Ionis製藥公司 Pnpla3表現之調節劑

Also Published As

Publication number Publication date
CN118891364A (zh) 2024-11-01
IL315078A (en) 2024-10-01
MX2024011595A (es) 2024-11-08
US20250207138A1 (en) 2025-06-26
AU2023237880A1 (en) 2024-09-12
TW202345869A (zh) 2023-12-01
CL2024002802A1 (es) 2025-02-07
JP2025512771A (ja) 2025-04-22
KR20240162559A (ko) 2024-11-15
EP4496893A2 (en) 2025-01-29
WO2023183801A2 (en) 2023-09-28
WO2023183801A3 (en) 2023-11-02
CA3254112A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
AR117297A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
JOP20230030A1 (ar) بنيات RNAi وطرق لتثبيط التعبير عن MARC1
WO2013176477A1 (ko) 세포 내 관통능을 가지는 rna 간섭을 유도하는 핵산 분자 및 그 용도
PE20230179A1 (es) Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
NI200700043A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan.
AR128877A1 (es) CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LOS MISMOS
CL2022003369A1 (es) Constructos de arni para inhibir la expresión de hsd17b13 y métodos de uso de los mismos
AR119061A1 (es) CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE SCAP Y MÉTODOS DE USO DE LAS MISMAS
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
CO2024013601A2 (es) Arnip que suprime la expresión del receptor de transferrina 2
CR20250267A (es) Inhibidores de polq
AR129710A1 (es) Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6)
CL2025004118A1 (es) Composiciones y métodos de inhibición de la adenilato ciclasa 9 (ac9).
AR134722A1 (es) Composición bioestimulante y métodos de uso
CL2024002825A1 (es) Compuestos de pirimid-2-il-prazol como inhibidores de irak.
MX2024014428A (es) Constructos de arni para inhibir la expresion de scap y metodos de utilizacion de los mismos
MX2026001746A (es) Sirna, conjugado de sirna, composicion farmaceutica y sus usos
CL2024001214A1 (es) Constructos de arni para inhibir la expresión de gpam y métodos de uso.
AR133964A1 (es) Región no traducida en 5’ no natural y uso de la misma
PE20240696A1 (es) Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
AR133998A1 (es) Agentes de interferencia de arn de ppp1r15b
KR102268702B1 (ko) Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
AR133967A1 (es) Región 3’ no traducida no natural y su uso
CL2025001781A1 (es) Constructos de arni para inhibir expresión de ttr y métodos de uso de los mismos
AR133298A1 (es) Arn guía manipulados por ingeniería o polinucleótidos dirigidos a dux4